Teva, MedinCell announce positive results for registration trial of TV-46000/mdc-IRM for patients with Schizophrenia
Trial enrollment was open to patients 13-65 years of age. In the RISE study, patients treated with the investigational subcutaneous risperidone injection either monthly (q1M) (n=183) or once